FDA preps for DMD drug gener­ics as Sarep­ta has yet to fin­ish its con­fir­ma­to­ry tri­al

The FDA typ­i­cal­ly re­leas­es guid­ance to help gener­ic drug man­u­fac­tur­ers de­vel­op new copy­cats of small mol­e­cule drugs, of­ten­times in prepa­ra­tion for a brand name prod­uct’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER